BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Centrum Broking Report
Aarti Drugs Ltd.'s Q4 FY24 result came above our estimate on all front, sales grew by 7% YoY (up 12% QoQ) to Rs 7.4 billion, mainly led by growth in the active pharma ingredient (10% YoY and 13% QoQ) and specialty chemicals (56% YoY and 29% QoQ).
On a sequential basis, the Ebitda margins improved by 196 basis points (flat YoY) to 12.6% due to operating leverage driven by improved capacity utilization.
Aarti Drugs' profit after tax for the quarter came in at Rs 562 million flat on YoY (up by 53% QoQ).
Further, commercialisation of majority capex from FY24 onwards, new launches and revenue recovery led by specialty chemical and API growth would boost earnings by 38% compound annual growth rate over FY23-25E.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
